XML 53 R44.htm IDEA: XBRL DOCUMENT v3.23.1
Assets and Liabilities Measured at Fair Value - Significant Unobservable Inputs (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable $ 12,668 $ 21,417
Discount rate    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable 12,668 $ 21,417
Callidus Biopharma Inc | Clinical and regulatory milestones | ATB200 Pompe Program    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration payable $ 12,668  
Callidus Biopharma Inc | Clinical and regulatory milestones | Probability of achievement of milestones | ATB200 Pompe Program | Minimum    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 88.00%  
Callidus Biopharma Inc | Clinical and regulatory milestones | Discount rate | Discount rate | ATB200 Pompe Program | Probability weighted discounted cash flow    
Fair Value Measurement Inputs and Valuation Techniques [Line Items]    
Contingent consideration, measurement input 11.20%